• Home
  •  / OraSure Technologies

OraSure Technologies

OverviewSuggest Edit

OraSure Technologies develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. The Company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. In addition, the Company offers oral fluid collection devices to collect, stabilize, transport, and store samples of genetic material. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing, immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications, an oral fluid HIV-1 confirmatory test and rapid point-of-care saliva alcohol test.

TypePublic
Founded1987
HQBethlehem, PA, USMap
Websiteorasure.com
Employee Ratings3.1More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)472(+19%)
Revenue (FY, 2020)$171.7 M(+12%)
Share Price (Dec 2021)$8.7(-1%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at OraSure Technologies

Michael Celano

Michael Celano

Chairman of the Board
Jack E. Jerrett

Jack E. Jerrett

Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Charles W. Patrick

Charles W. Patrick

Director
Mara G. Aspinall

Mara G. Aspinall

Director
Eamonn Hobbs

Eamonn Hobbs

Director
David Rappaport

David Rappaport

Senior Vice President, Business Development
Show more

OraSure Technologies Office Locations

OraSure Technologies has offices in Bethlehem and Houston
Bethlehem, PA, US (HQ)
220 E 1st St
Bethlehem, PA, US
150 Webster St
Bethlehem, PA, US
1745 Eaton Ave
Bethlehem, PA, US
2500 Emrick Blvd #100
Houston, TX, US
2450 Holcombe Blvd
Show all (5)

OraSure Technologies Financials and Metrics

OraSure Technologies Revenue

Embed Graph
View revenue for all periods
OraSure Technologies's revenue was reported to be $171.72 m in FY, 2020
USD

Revenue (Q2, 2021)

1.9m

Market capitalization (31-Dec-2021)

635.4m

Closing stock price (31-Dec-2021)

8.7

Cash (31-Mar-2021)

177.7m

EV

463.5m
OraSure Technologies's current market capitalization is $635.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

81.9m87.8m98.9m106.5m119.7m128.2m167.1m181.7m154.6m171.7m

Revenue growth, %

9%7%13%8%12%7%

Cost of goods sold

30.2m32.2m40.4m39.8m39.4m40.2m68.1m68.1m60.0m69.9m

Gross profit

51.7m55.6m58.6m66.6m80.3m88.0m99.0m113.6m94.6m101.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

19.1m21.7m20.9m22.6m22.1m21.2m24.3m24.7m23.5m26.4m27.8m27.1m30.4m29.9m29.1m31.4m32.3m32.5m40.2m42.3m42.0m43.6m45.9m30.1m38.8m36.0m31.6m29.3m48.0m58.6m1.9m

Cost of goods sold

6.8m8.1m7.2m7.9m8.2m9.1m9.8m9.7m9.6m10.4m9.1m10.1m9.7m9.2m8.8m10.3m9.6m12.2m14.7m17.7m17.5m17.7m17.3m12.0m13.8m14.3m15.5m12.0m17.7m20.3m

Gross profit

12.3m13.6m13.7m14.7m13.9m12.0m14.5m14.9m13.9m16.0m18.7m17.0m20.7m20.7m20.3m21.1m22.7m20.3m25.5m24.6m24.5m25.9m28.5m18.1m25.0m21.6m16.1m17.3m30.3m38.3m

Gross profit Margin, %

64%63%66%65%63%57%60%61%59%61%67%63%68%69%70%67%70%62%63%58%58%59%62%60%64%60%51%59%63%65%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

23.9m87.9m93.2m92.9m94.1m108.0m71.0m88.4m75.7m160.8m

Accounts Receivable

17.2m17.5m13.0m16.1m19.3m42.5m34.8m36.9m38.8m

Prepaid Expenses

1.7m1.7m1.7m1.1m1.5m1.7m1.9m2.4m3.9m

Inventories

9.6m12.8m11.4m15.8m13.2m11.8m19.3m22.9m23.2m31.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

75.4m21.4m22.8m23.3m89.4m79.3m77.0m82.6m84.2m75.8m93.9m85.5m83.4m100.7m94.6m105.7m111.7m120.9m104.9m76.8m64.0m71.0m78.1m69.5m72.6m85.5m83.4m173.9m162.9m177.7m

Accounts Receivable

11.7m14.4m13.3m15.4m19.3m17.0m15.4m14.3m13.3m14.2m14.9m16.4m16.4m17.1m16.7m18.4m15.5m24.0m26.7m28.1m28.2m31.6m33.3m24.9m29.4m27.8m27.9m25.9m30.6m36.4m

Prepaid Expenses

1.7m1.5m2.1m2.2m1.5m3.2m2.5m2.0m2.0m1.5m1.1m1.6m1.6m1.4m2.1m1.9m1.4m1.7m1.3m1.2m2.2m1.5m1.4m2.6m2.1m1.8m2.9m2.7m2.5m6.0m

Inventories

8.1m9.4m10.8m11.0m12.8m13.1m12.5m12.0m12.0m13.2m14.8m15.6m15.7m15.0m12.3m11.4m12.1m12.7m14.5m16.9m20.9m20.6m19.9m26.2m25.7m25.0m22.7m27.7m30.5m40.4m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(8.8m)(15.1m)(11.2m)(4.6m)8.2m19.7m30.9m20.4m16.7m(14.9m)

Depreciation and Amortization

4.9m7.3m6.6m6.3m5.7m5.7m6.4m6.5m7.3m9.4m

Inventories

(1.8m)(3.1m)1.3m(4.4m)2.3m1.5m(7.4m)(3.9m)(1.3m)(8.6m)

Accounts Payable

911.1k(791.0k)1.5m2.2m(2.6m)46.0k5.2m208.0k(1.5m)7.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(5.0m)(9.0m)(3.3m)(6.8m)(9.2m)(10.2m)(15.5m)(17.4m)(5.6m)(3.1m)(2.0m)113.0k2.1m3.6m2.4m6.3m12.5m12.4m17.9m23.6m(2.1m)2.0m10.1m(3.3m)1.1m14.2m(7.3m)(17.8m)(16.8m)3.8m2.4m

Depreciation and Amortization

1.7m3.0m1.8m3.6m5.5m1.6m3.2m4.8m1.5m3.1m4.7m1.4m2.8m4.3m1.4m2.8m4.2m1.4m2.9m4.6m1.9m3.7m5.6m1.7m3.6m5.5m2.2m4.6m7.1m2.5m5.1m

Inventories

(801.0k)(1.5m)(1.2m)(1.4m)(3.2m)(312.0k)229.0k745.0k(586.0k)(1.8m)(3.4m)57.0k35.0k633.0k990.0k1.9m1.2m(893.0k)(2.7m)(4.9m)(1.7m)(1.4m)(649.0k)(2.9m)(2.3m)(3.3m)248.0k(4.7m)(7.4m)(8.4m)(16.1m)

Accounts Payable

825.3k268.3k(638.2k)151.2k953.1k2.3m40.0k497.0k(683.0k)(179.0k)(284.0k)(2.1m)(2.5m)(72.0k)758.0k(782.0k)(125.0k)2.6m4.7m4.6m(1.1m)(193.0k)(2.2m)(253.0k)81.0k(1.0m)(3.1m)(605.0k)3.3m(253.0k)4.4m
show all
USDQ2, 2011

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

OraSure Technologies Operating Metrics

FY, 2016

Facilities

2

Patents (US)

29
Show all operating metrics

OraSure Technologies Revenue Breakdown

Embed Graph

OraSure Technologies revenue breakdown by business segment: 74.9% from OSUR and 25.1% from DNAG

OraSure Technologies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

OraSure Technologies Online and Social Media Presence

OraSure Technologies's Trends

Embed Graph

OraSure Technologies News and Updates

December 14, 2021

OraSure Technologies Announces 2022 Annual Meeting Date

BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022. The record date for the Meeting will be March 27, 2022. Only …
November 30, 2021

OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus

Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City
November 09, 2021

OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Com…
November 08, 2021

OraSure Technologies Appoints Two New Members to the Board of Directors

New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience
September 02, 2021

OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan

Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO
June 17, 2021

OraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference

BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in …
Show more

OraSure Technologies Blogs

January 13, 2022

Scott Gleason

Scott Gleason alfredo.macaba… Thu, 01/13/2022 - 18:09 Scott Gleason Interim CFO, Senior Vice President Corporate Communications & Investor Relations Scott Gleason joined OraSure in May of 2021 serving as the Senior Vice President of In…
January 13, 2022

Anne C. Whitaker

Anne C. Whitaker alfredo.macaba… Thu, 01/13/2022 - 17:48 Anne C. Whitaker Managing Partner Anne Whitaker Group, LLC Anne C. Whitaker became a board member in November 2021 and serves on the Audit Committee. Mrs. Whitaker is a seasoned he…
January 13, 2022

Nancy J. Gagliano, MD, MBA

Nancy J. Gagliano, MD, MBA alfredo.macaba… Thu, 01/13/2022 - 17:45 Nancy J. Gagliano, MD, MBA Managing Director Granite Healthcare Advisors Nancy J. Gagliano, MD, MBA, became a board member in November 2021 and serves on the Nominating a…
January 13, 2022

InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants

InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants jo-en.bautista… Thu, 01/13/2022 - 16:05 InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants January 13, 2022 at 4:05 PM EST This release is a backfill f…
November 03, 2021

OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22

Third quarter revenue of $53.9 million grew 12% year-over-year; excluding COVID-19 product revenues, revenues for the quarter grew 37% from the prior year, demonstrating strong growth OraSure signs three major U.S. government contracts providing $205 million in government InteliSwab ™ procurement,
October 27, 2021

OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET

OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET Content Import Wed, 10/27/2021 - 07:05 OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET October 27, 2021 at 7:…
Show more

 OraSure Technologies Frequently Asked Questions

  • When was OraSure Technologies founded?

    OraSure Technologies was founded in 1987.

  • Who are OraSure Technologies key executives?

    OraSure Technologies's key executives are Michael Celano, Jack E. Jerrett and Charles W. Patrick.

  • How many employees does OraSure Technologies have?

    OraSure Technologies has 472 employees.

  • What is OraSure Technologies revenue?

    Latest OraSure Technologies annual revenue is $171.7 m.

  • What is OraSure Technologies revenue per employee?

    Latest OraSure Technologies revenue per employee is $363.8 k.

  • Who are OraSure Technologies competitors?

    Competitors of OraSure Technologies include Antylia Scientific, Patterson Veterinary Supply and ROXALL.

  • Where is OraSure Technologies headquarters?

    OraSure Technologies headquarters is located at 220 E 1st St, Bethlehem.

  • Where are OraSure Technologies offices?

    OraSure Technologies has offices in Bethlehem and Houston.

  • How many offices does OraSure Technologies have?

    OraSure Technologies has 5 offices.